Does Estrogen Convert to Testosterone?

Estrogen does not convert to testosterone. The enzymatic pathway runs in one direction: testosterone is converted into estradiol (the most potent estrogen) by an enzyme called aromatase, but no known enzyme in the human body reverses that reaction. This is one of the most common misunderstandings in hormone biology, and it matters because people make real decisions about supplements, medications, and hormone therapy based on the assumption that these conversions can go both ways. The reality is more interesting and, in places, more complicated than a simple yes-or-no suggests.

The One-Way Street From Androgen to Estrogen

The body builds sex hormones from cholesterol in a stepwise assembly line. Along this line, androgens (the family that includes testosterone) are converted into estrogens by the aromatase enzyme. Aromatase converts testosterone into estradiol, and it converts a weaker androgen called androstenedione into estrone, a less potent estrogen.¹ This is genuinely a one-way reaction. There is no “reverse aromatase” that strips the estrogen molecule back into testosterone. Once testosterone has been aromatized, that molecule’s life as an androgen is over.

This matters because estrogen sits downstream of testosterone on the steroid synthesis pathway. Thinking of it as a family tree helps: cholesterol is the great-grandparent, progesterone and its relatives are the middle generation, androgens like testosterone are the next branch down, and estrogens are the end of the line on that particular branch. You can move forward along this tree but not backward. Enzymes exist to catalyze each forward step, and no enzyme catalyzes the reverse step from estrogen to testosterone.

Why the Confusion Exists

Several real biological phenomena create the impression that estrogen and testosterone trade places freely. Understanding why the confusion arises helps clear it up.

First, estrogen and testosterone genuinely do affect each other’s levels, just not through direct chemical conversion. When you give someone exogenous estrogen, their testosterone drops. This is an indirect effect working through the brain’s feedback system: high estrogen signals to the pituitary gland that sex hormone levels are adequate, so the pituitary dials back the hormones that tell the gonads to produce testosterone. In transgender women receiving estrogen therapy, testosterone levels can fall dramatically, from roughly 730 ng/dL down to about 18 ng/dL, without any estrogen molecule physically turning into testosterone or vice versa.² The estrogen suppresses testosterone production by shutting down the upstream signals.³

Second, people sometimes see their estrogen levels rise when they take testosterone (or vice versa, see testosterone rise in conditions associated with estrogen changes) and assume the hormones are converting back and forth. When testosterone rises, some of it genuinely does convert into estrogen via aromatase, so estrogen goes up too. But the reverse does not happen. When estrogen rises on its own, testosterone does not appear from it. Any change in testosterone is coming from the feedback loop described above, or from changes in how much testosterone is bound to carrier proteins in the blood.

What Aromatase Inhibitors Actually Do

If estrogen were convertible back into testosterone, blocking aromatase would make no difference to testosterone levels, since the body could just run the reaction in reverse. But aromatase inhibitors tell a clear story: by blocking the one-way conversion of testosterone to estrogen, they cause testosterone to accumulate. In men, aromatase inhibitors effectively raise testosterone levels because the testosterone that would have been converted into estradiol stays as testosterone instead.⁴

In oncology, aromatase inhibitors are used for a related but distinct reason. Many breast cancers grow in response to estrogen, and the body makes estrogen partly by aromatizing androgens in fat tissue, the adrenal glands, and even within the tumor itself. Blocking aromatase cuts off the supply of estrogen to the tumor.⁵ The existence of these drugs and their effectiveness is itself proof that the testosterone-to-estrogen pathway is one-directional. If estrogen could convert back, blocking aromatase would just cause estrogen to take the reverse route. It does not.

Enzymes That Activate Estrogens Without Involving Testosterone

There is another enzymatic system that sometimes gets dragged into this conversation. A family of enzymes called 17-beta-hydroxysteroid dehydrogenases (17β-HSDs) can interconvert between weaker and stronger forms of the same hormone class. For example, 17β-HSD type 1 converts the weak estrogen estrone into the potent estrogen estradiol in the ovary’s granulosa cells, promoting follicle maturation.⁶ This is not a conversion from estrogen to testosterone; it is a conversion from a weak estrogen to a strong estrogen. Similarly, other members of this enzyme family can convert weak androgens into strong androgens. The key point is that these enzymes work within a hormone class, not across the androgen-estrogen divide.

People sometimes read about 17β-HSD enzymes and assume the body has a toolkit for freely shuffling hormones in any direction. It does not. Activating estrone into estradiol is like adjusting the volume knob on estrogen, not switching the channel to testosterone.

The Backdoor Pathway to Androgens

There is a genuinely surprising wrinkle in steroid biochemistry that makes the hormone landscape more complex than textbooks used to suggest. Researchers have discovered an alternative route for making dihydrotestosterone (DHT), a potent androgen, that does not go through testosterone at all.⁷ This “backdoor pathway” starts from progesterone-related precursors, gets modified by a different sequence of enzymes, and ends up at DHT without testosterone ever appearing as an intermediate.⁸

This pathway was originally identified in marsupials and subsequently confirmed in humans.⁹ It matters for understanding certain disorders of sex development, where fetuses are exposed to DHT from this backdoor route even when the standard testosterone pathway is impaired. But even this alternative pathway does not involve converting estrogen into an androgen. It bypasses testosterone, starting from cholesterol-derived precursors that are upstream of both androgens and estrogens. So while the steroid synthesis map is more tangled than older textbooks showed, the estrogen-to-testosterone conversion still does not exist anywhere on it.

When Aromatase Is Missing Entirely

Aromatase deficiency is a rare genetic condition that illustrates what happens when the body cannot convert androgens into estrogens at all. In affected pregnancies, the fetal adrenal gland produces large amounts of androgen precursors (particularly DHEA sulfate) that the placenta normally converts into estrogens. Without functional aromatase, those precursors instead accumulate as testosterone and DHT. The result can be severe: female fetuses develop ambiguous genitalia from androgen exposure, and the mother herself can become virilized during pregnancy, developing acne, deepening voice, and excess body hair.¹⁰

After birth, people with aromatase deficiency have extremely low estrogen levels and relatively high androgen levels, since none of their androgens are being siphoned off into estrogen production. This condition underscores the one-way nature of the aromatase reaction. The body accumulates androgens when it cannot convert them to estrogens, but it does not find an alternative way to make estrogens from something else. There is no backup enzyme working in the reverse direction.

How PCOS Shifts the Balance

Polycystic ovary syndrome is one of the most common hormonal conditions in women of reproductive age, and it involves both androgens and estrogens, though not through direct interconversion. In PCOS, the ovarian follicles stall during development. A hormone called anti-Müllerian hormone (AMH) builds up as more follicles arrest, and elevated AMH suppresses aromatase expression in the granulosa cells. With less aromatase activity, fewer androgens get converted into estrogens, and androgen levels rise.¹¹

This is a case where aromatase underperformance leads to androgen excess, not a case of estrogen converting into testosterone. The mechanism is a bottleneck: the forward conversion from androgen to estrogen slows down, so androgens pile up. Women with PCOS often have higher testosterone and lower or disrupted estrogen patterns, but the testosterone is not coming from estrogen. It is coming from the same precursors it always does; it just is not being cleared into estrogen as efficiently.

Estrogen Therapy and Sex Hormone Binding Globulin

When postmenopausal women take oral estrogen replacement, something happens that can look like a change in testosterone levels on a lab report, even though no conversion is occurring. Oral estrogen passes through the liver on first pass, and the liver responds by producing more of a carrier protein called sex hormone binding globulin (SHBG). SHBG binds to testosterone in the blood, making it unavailable to tissues. So the total testosterone might stay roughly the same, but the free (active) testosterone effectively drops. One study found that oral estrogen replacement significantly increased SHBG levels, while transdermal estrogen (delivered through the skin, bypassing the liver) did not.¹²

This is clinically relevant because a woman on oral estrogen might notice symptoms consistent with lower androgen activity (lower libido, for instance) and assume the estrogen “turned into” something that displaced her testosterone. What actually happened is that her liver made more SHBG, which grabbed onto her existing testosterone and pulled it out of circulation. The testosterone molecules are still there; they are just bound up and inactive. Transdermal estrogen largely avoids this effect because it enters the bloodstream without making that first pass through the liver.

Your Brain Makes Its Own Hormones

One of the more fascinating areas of recent research is the discovery that the brain synthesizes its own sex steroids, independent of what is circulating in the blood. The brain expresses aromatase, and neurons can locally convert testosterone into estradiol right at the synapse.¹³ These locally made neurosteroids, sometimes called neuro-estradiol and neuro-testosterone, play roles in memory, learning, and protecting neurons from age-related decline.¹⁴

Even in the brain, though, the direction of conversion is the same: androgen to estrogen, never the reverse. Neurons that express aromatase take locally available testosterone and turn it into estradiol to fine-tune synaptic activity. The brain has its own small-scale hormone factory, but the factory’s assembly line runs in the same direction as every other tissue in the body. The reason this matters is that circulating hormone levels on a blood test do not fully capture what is happening inside the brain. A person with modest blood testosterone might still have meaningful neuro-estradiol production in the hippocampus, and this local production responds to neural activity rather than to pituitary signals. It is a reminder that the hormone story is richer than what shows up on a lab panel.

Androgens as Estrogen Precursors in Cancer

In breast cancer biology, the relationship between androgens and estrogens takes on particular clinical importance. Many breast cancers are estrogen-receptor positive, meaning they grow in response to estrogen. In postmenopausal women, the ovaries are no longer the primary estrogen source. Instead, aromatase in fat tissue, the adrenal glands, and sometimes within the tumor itself converts circulating androgens into estrogens that feed the cancer.⁵ This is why aromatase inhibitors have become a cornerstone of breast cancer treatment: they cut off the local production of estrogen from androgen precursors.

But androgens are not just passive raw material for estrogen production. Breast cancer cells often express androgen receptors too, and androgens binding to those receptors can have their own direct effects on tumor growth, sometimes inhibitory, sometimes stimulatory depending on the cancer subtype. The picture is complicated enough that oncologists cannot simply think of testosterone as “future estrogen.” It is both a hormone with its own receptor-mediated effects and a precursor that gets aromatized into estrogen. The one thing it is not is a product of estrogen conversion. Even in the tumor microenvironment, where enzymatic activity can be unusually high, the conversion arrow points one way.

Supplements and “Estrogen Blockers”

A substantial market exists for supplements marketed as estrogen blockers or testosterone boosters, often sold with the implication that blocking estrogen will raise testosterone. The kernel of truth here is real: if you reduce aromatase activity, less testosterone gets converted to estrogen, so testosterone levels can rise. This is the legitimate pharmacological principle behind prescription aromatase inhibitors.⁴

Where the marketing gets misleading is in suggesting that estrogen in your body is somehow “stealing” your testosterone, as if the two are in a tug of war and blocking one automatically boosts the other. The reality is more specific: only the fraction of testosterone that encounters aromatase gets converted. In a healthy young man, this is a relatively small fraction, and the feedback loop between the brain and the testes keeps testosterone production well-regulated. Taking an over-the-counter supplement that mildly inhibits aromatase is unlikely to produce the dramatic testosterone increases that the branding implies, and doing so without medical supervision can create problems, because men need some estrogen for bone density, cardiovascular health, and brain function. Prescription aromatase inhibitors are used in specific clinical situations under monitoring, not as general-purpose testosterone boosters.

If you see a product claiming it “converts estrogen back to testosterone,” that is not how any known human enzyme works. The product might reduce aromatase activity, it might block estrogen receptors, or it might do nothing at all. But it is not reversing the aromatase reaction, because that reaction does not reverse.